Three-month tolerability of orlistat in adolescents with obesity-related comorbid conditions

Obesity Research

Volumn 10, Issue 7, 2002, Pages 642-650

  McDuffie, Jennifer R ^a   Calis, Karim A ^b   Uwaifo, Gabriel I ^a   Sebring, Nancy G ^c   Fallon, Erica M ^a   Hubbard, Van S ^d   Yanovski, Jack A ^a  

^a EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH AND HUMAN DEVELOPMENT   (United States)

^b Amer Soc Hlth Syst Pharmacists   (United States)

^c NATIONAL INSTITUTES OF HEALTH   (United States)

^d NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES   (United States)

Author keywords

Adolescence; Obesity; Orlistat; Pharmacotherapy; Weight loss

Indexed keywords

CHOLESTEROL; INSULIN; LACTONE; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TETRAHYDROLIPSTATIN; VITAMIN; VITAMIN D;

ADOLESCENT; ARTICLE; BLOOD; BODY MASS; CLINICAL TRIAL; DIET RESTRICTION; DIET SUPPLEMENTATION; FEMALE; GLUCOSE BLOOD LEVEL; GLUCOSE TOLERANCE TEST; HUMAN; MALE; OBESITY; PILOT STUDY; TREATMENT OUTCOME; WEIGHT REDUCTION;

ADOLESCENT; BLOOD GLUCOSE; BODY MASS INDEX; CHOLESTEROL; CHOLESTEROL, LDL; DIETARY SUPPLEMENTS; FASTING; FEMALE; GLUCOSE TOLERANCE TEST; HUMANS; INSULIN; LACTONES; MALE; OBESITY; PILOT PROJECTS; TREATMENT OUTCOME; VITAMIN D; VITAMINS; WEIGHT LOSS;

EID: 0036633087     PISSN: 10717323     EISSN: None     Source Type: Journal    
DOI: 10.1038/oby.2002.87     Document Type: Article

References (56)

1. National Center for Health Statistics. Health, United States, 2000. Washington, DC: National Center for Health Statistics; 2001.
2. National Center for Health Statistics. Prevalence of Overweight among Children and Adolescents: United States, 1999. Washington, DC: National Center for Health Statistics; 2001.
3. Must A, Strauss RS. Risks and consequences of childhood and adolescent obesity. Int J Obes Relat Metab Disord. 1999; 23(Suppl 2):S2-11.
4. Maffeis C. Aetiology of overweight and obesity in children and adolescents. Eur J Pediatr. 2000;159(Suppl 1):S35-44.
5. Jeffery RW, Drewnowski A, Epstein LH, et al. Long-term maintenance of weight loss: current status. Health Psychol. 2000;19:5-16.
6. Haddock C, Shadish W, Klesges R, Stein R. Treatments for childhood and adolescent obesity. Ann Behav Med. 1994;16: 235-44.
7. DeWolfe JA, Jack E. Weight control in adolescent girls: a comparison of the effectiveness of three approaches to follow-up. J Sch Health. 1984;54:347-9.
8. Mellin LM, Stinkard LA, Irwin CE, Jr. Adolescent obesity intervention: validation of the SHAPEDOWN program. J Am Diet Assoc. 1987;87:333-8.
9. Hoerr SL, Nelson RA, Essex-Sorlie D. Treatment and follow-up of obesity in adolescent girls. J Adolesc Health Care. 1988;9:28-37.
10. Wadden TA, Stunkard AJ, Rich L, Rubin CJ, Sweidel G, McKinney S. Obesity in black adolescent girls: a controlled clinical trial of treatment by diet, behavior modification, and parental support. Pediatrics. 1990;85:345-52.
11. Thomas-Dobersen DA, Butler-Simon N, Fleshner M. Evaluation of a weight management intervention program in adolescents with insulin-dependent diabetes mellitus. J Am Diet Assoc. 1993;93:535-40.
12. Gately PJ, Cooke CB, Butterly RJ, Mackreth P, Carroll S. The effects of a children's summer camp programme on weight loss, with a 10 month follow-up. Int J Obes Relat Metab Disord. 2000;24:1445-52.
13. Rocchini AP, Katch V, Schork A, Kelch RP. Insulin and blood pressure during weight loss in obese adolescents. Hypertension. 1987;10:267-73.
14. Becque MD, Katch VL, Rocchini AP, Marks CR, Moorehead C. Coronary risk incidence of obese adolescents: reduction by exercise plus diet intervention. Pediatrics. 1988;81: 605-12.
15. Mittendorfer B, Ostlund RJ, Patterson B, Klein S. Orlistat inhibits dietary cholesterol absorption. Obes Res. 2001;9: 599-604.
16. Guerciolini R. Mode of action of orlistat. Int J Obes Relat Metab Disord. 1997;21(Suppl 3:812-23.
17. Rossner S, Sjöström L, Noack R, Meinders AE, Noseda G. Weight loss, weight maintenance, and improved cardiovascular risk factors after 2 years treatment with orlistat for obesity. European Orlistat Obesity Study Group. Obes Res. 2000;8: 49-61.
18. Davidson MH, Hauptman J, DiGirolamo M, et al. Weight control and risk factor reduction in obese subjects treated for 2 years with orlistat: a randomized controlled trial. JAMA. 1999;281:235-42.
19. Drent ML, van der Veen EA. First clinical studies with orlistat: a short review. Obes Res. 1995;3(Suppl 4): 623S-625S.
20. Finer N, James WP, Kopelman PG, Lean ME, Williams G. One-year treatment of obesity: a randomized, double-blind, placebo-controlled, multicentre study of orlistat, a gastrointestinal lipase inhibitor. Int J Obes Relat Metab Disord. 2000; 24:306-13.
21. Hauptman J, Lucas C, Boldrin MN, Collins H, Segal KR. Orlistat in the long-term treatment of obesity in primary care settings. Arch Fam Med. 2000;9:160-7.
22. Hollander PA, Elbein SC, Hirsch IB, et al. Role of orlistat in the treatment of obese patients with type 2 diabetes. A 1-year randomized double-blind study. Diabetes Care. 1998; 21:1288-94.
23. James WP, Avenell A, Broom J, Whitehead J. A one-year trial to assess the value of orlistat in the management of obesity. Int J Obes Relat Metab Disord. 1997;21(Suppl 3): S24-30.
24. Karhunen L, Franssila-Kallunki A, Rissanen P, et al. Effect of orlistat treatment on body composition and resting energy expenditure during a two-year weight-reduction programme in obese Finns. Int J Obes Relat Metab Disord. 2000;24:1567-72.
25. Lindgarde F. The effect of orlistat on body weight and coronary heart disease risk profile in obese patients: the Swedish Multimorbidity Study. J Intern Med. 2000;248:245-54.
26. Sjöström L, Rissanen A, Andersen T, et al. Randomised placebo-controlled trial of orlistat for weight loss and prevention of weight regain in obese patients. European Multicentre Orlistat Study Group. Lancet. 1998;352:167-72.
27. Van Gaal LF, Broom JI, Enzi G, Toplak H. Efficacy and tolerability of orlistat in the treatment of obesity: a 6-month dose-ranging study. Orlistat Dose-Ranging Study Group. Eur J Clin Pharmacol. 1998;54:125-32.
28. Zavoral JH. Treatment with orlistat reduces cardiovascular risk in obese patients. J Hypertens. 1998;16:2013-7.
29. Lohman T, Roche A, Martorell R. Anthropometric Standardization Reference Manual. Champagne, IL: Human Kinetics Books; 1988, pp. 41-51 and pp. 57-69.
30. Dempster P, Aitkens S. A new air displacement method for the determination of human body composition. Med Sci Sports Exerc. 1995;27:1692-7.
31. McCrory MA, Gomez TD, Bernauer EM, Mole PA. Evaluation of a new air displacement plethysmograph for measuring human body composition. Med Sci Sports Exerc. 1995;27: 1686-91.
32. Levenhagen DK, Borel MJ, Welch DC, et al. A comparison of air displacement plethysmography with three other techniques to determine body fat in healthy adults. JPEN J Parenter Enteral Nutr. 1999;23:293-9.
33. Biaggi RR, Vollman MW, Nies MA, et al. Comparison of air-displacement plethysmography with hydrostatic weighing and bioelectrical impedance analysis for the assessment of body composition in healthy adults. Am J Clin Nutr. 1999;69: 898-903.
34. Lockner DW, Heyward VH, Baumgartner RN, Jenkins KA. Comparison of air-displacement plethysmography, hydrodensitometry, and dual X-ray absorptiometry for assessing body composition of children 10 to 18 years of age. Ann NY Acad Sci. 2000;904:72-8.
35. Siri W. Body composition from fluid spaces and density: analysis of methods. In: Brozek J, Honschel A, eds. Techniques for Measuring Body Composition. Washington, DC: National Academy of Sciences/National Research Council; 1961:223-4.
36. Nixon DE, Moyer TP, Johnson P, et al. Routine measurement of calcium, magnesium, copper, zinc, and iron in urine and serum by inductively coupled plasma emission spectroscopy. Clin Chem. 1986;32:1660-5.
37. McClean SW, Ruddel ME, Gross EG, DeGiovanna JJ, Peck GL. Liquid-chromatographic assay for retinol (vitamin A) and retinol analogs in therapeutic trials. Clin Chem. 1982; 28:693-6.
38. Hollis BW, Kamerud JQ, Selvaag SR, Lorenz JD, Napoli JL. Determination of vitamin D status by radioimmunoassay with an 1251-labeled tracer. Clin Chem. 1993;39:529-33.
39. Davidson KW, Sadowski JA. Determination of vitamin K compounds in plasma or serum by high-performance liquid chromatography using postcolumn chemical reduction and fluorimetric detection. Methods Enzymol. 1997;282:408-21.
40. Jansson L, Nilsson B, Lindgren R. Quantitation of serum tocopherols by high-performance liquid chromatography with fluorescence detection. J Chromatogr. 1980;181:242-7.
41. DiSanto AR, Wagner JG. Pharmacokinetics of highly ionized drugs. II. Methylene blue-absorption, metabolism, and excretion in man and dog after oral administration. J Pharm Sci. 1972;61:1086-90.
42. Bergman RN. Lilly lecture 1989. Toward physiological understanding of glucose tolerance. Minimal-model approach. Diabetes. 1989;38:1512-27.
43. Boden G, Reichard G, Hoeldtke R, Rezvzni I, Owen O. Severe insulin-induced hypoglycemia experienced by patients with type 2 diabetes associated with deficiencies in the release of counterregulatory hormones. N Engl J Med, 1981;305: 1200-5.
44. Hepburn D, MacLeod K, Pell A, Scougal I, Frier B. Frequency and symptoms of hypoglycemia experienced by patients with type 2 diabetes treated with insulin. Diabet Med. 1993;10:231-7.
45. Corso DM, Pucino F, DeLeo JM, Calis KA, Gallelli JF. Development of a questionnaire for detecting potential adverse drug reactions. Ann Pharmacother. 1992;26:890-6.
46. Clemens TL, Adams JS, Henderson SL, Holick MF. Increased skin pigment reduces the capacity of skin to synthesise vitamin D3. Lancet. 1982;1:74-6.
47. Matsuoka LY, Wortsman J, Haddad JG, Kolm P, Hollis BW. Racial pigmentation and the cutaneous synthesis of vitamin D. Arch Dermatol. 1991;127:536-8.
48. Matsuoka LY, Wortsman J, Chen TC, Holick MF. Com pensation for the interracial variance in the cutaneous synthesis of vitamin D. J Lab Clin Med. 1995;126:452-7.
49. Drent ML, Popp-Snijders C, Ader HJ, Jansen JB, van der Veen EA. Lipase inhibition and hormonal status, body composition and gastrointestinal processing of a liquid high-fat mixed meal in moderately obese subjects. Obes Res. 1995;3: 573-81.
50. Beermann B, Melander H, Sawe J, Ulleryd C, Dahlqvist R. Incorrect use and limited weight reduction of orlistat (Xeical) in clinical practice. A cohort study. Eur J Clin Pharmacol. 2001;57:309-11.
51. Wadden TA, Van Itallie TB, Blackburn GL. Responsible and irresponsible use of very-low-calorie diets in the treatment of obesity. JAMA. 1990;263:83-5.
52. Kay JP, Alemzadeh R, Langley G, D'Angelo L, Smith P, Holshouser S. Beneficial effects of metformin in normoglycemic morbidly obese adolescents. Metabolism. 2001;50:1457-61.
53. Freemark M, Bursey D. The effects of metformin on body mass index and glucose tolerance in obese adolescents with fasting hyperinsulinemia and a family history of type 2 diabetes. Pediatrics. 2001;107:E55.
54. Heck AM, Yanovski JA, Calis KA. Orlistat, a new lipase inhibitor for the management of obesity. Pharmacotherapy. 2000;20:270-9.
55. Tonstad S, Pometta D, Erkelens DW, et al. The effect of the gastrointestinal lipase inhibitor, orlistat, on serum lipids and lipoproteins in patients with primary hyperlipidaemia. Eur J Clin Pharmacol. 1994;46:405-10.
56. Heymsfield SB, Segal KR, Hauptman J, et al. Effects of weight loss with orlistat on glucose tolerance and progression to type 2 diabetes in obese adults. Arch Intern Med. 2000;160: 1321-6.